Skip to main content
. 2022 Aug 13;14(16):3915. doi: 10.3390/cancers14163915

Figure 3.

Figure 3

FAM107A exhibits low expression in prostate cancer cells due to hypermethylation of its promoter region. (A) cg04992588, cg24659328, cg2615468, and cg01446993 were used as probes to detect the promoter methylation level of the FAM107A gene in normal and tumor tissues (http://www.bioinfo-zs.com/smartapp/ (accessed on 1 June 2022)). (B) cg04992588, cg24659328, cg2615468, and cg01446993 probes were negatively correlated with FAM107A gene expression. (C) Growth inhibitory effect of different concentrations of 5-Aza on prostate cancer cells. (D) The methylation region of the promoter (CpG island) of the primer. (E) MSP analysis of the methylation status of the FAM107A promoter before and after 5-azacytidine treatment. “ U “indicates amplification without methylation, and” M “indicates amplification with methylation. (F) 5-Aza treatment rescues the mRNA expression of FAM107A. (G) Effect of 5-azacytidine on FAM107A protein expression in prostate cancer cells by Western blotting. (H)Analysis of the effects of 5-Aza and FAM107A siRNA on cell proliferation according to a CCK8 assay. (I) Correlation between FAM107A and DNMT1 was analyzed using the prostate cancer dataset included in the Cbioportal database (https://www.cbioportal.org/ (accessed on 1 June 2022)). (J) Effect of DNMT1 on FAM107A protein expression in prostate cancer cells as determined by Western blotting. *** for p < 0.001, ** for p < 0.01 and * for p < 0.05.